CEPS: The QE Placebo

12 June 2015

After six months since the ECB's QE programme started, its real impact in European economy remains difficult to assess.

It has now been nearly half a year since the European Central Bank declared its intention to buy some €1.1 trillion ($1.3 trillion) worth of eurozone bonds. When it first announced the so-called ‘extended asset-purchase programme’ in January, the ECB emphasised that it was only expanding an existing programme, under which it had been buying modest quantities of private-sector bonds, to government paper. But this pretence of continuity was just that: a pretence.

In reality, by purchasing large volumes of government bonds, the ECB was crossing the Rubicon; after all, it is explicitly prohibited from financing governments. The ECB’s defence was that that the programme was the only way to move inflation closer to its target of close to 2%. Moreover, it pointed out, it was merely following the example of other major central banks, including the Bank of England, the Bank of Japan, and especially the US Federal Reserve, whose programme of quantitative easing (QE) entailed the purchase of more than $2 trillion worth of long-term securities from 2008 to 2012.

Legal uncertainty aside, whether the ECB’s decision to pursue QE can be justified ultimately depends on its impact. But after six months, that impact remains difficult to assess.

Full publication


© CEPS - Centre for European Policy Studies